Hematopoietic stem cell transplantation for new-onset type 1 diabetes

This study aims to determine the safety and the efficacy of autologous hematopoietic stem cell transplantations toward reconstitution of the immune system and β-cell preservation. Hematopoietic stem cells are mobilized with cyclophosphamide (2.0 g/m^2) and granulocyte colony stimulating factor (10 μg/kg per day), collected from peripheral blood by leukapheresis and then cryopreserved. Transplantation improved β-cell function by creating a more tolerant immune system and no severe adverse effects.